Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases?-Reference-Cited by-同舟云学术

Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases?

Published:2024-03-31 Issue:1 Volume:33 Page:
ISSN:0803-7051
Container-title:Blood Pressure
language:en
Short-container-title:Blood Pressure

Author:

Kjeldsen Sverre E.¹^ORCID,Egan Brent M.²^ORCID,Burnier Michel³^ORCID,Narkiewicz Krzysztof⁴^ORCID,Kreutz Reinhold⁵^ORCID,Mancia Giuseppe⁶^ORCID

Affiliation:

1. Departments of Cardiology and Nephrology, University of Oslo Ullevaal Hospital, Oslo, Norway

2. American Medical Association, University of SC, Greenville, SC, USA

3. Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

4. Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland

5. Institute of Clinical Pharmacology and Toxicology, Charité-University Medicine, Berlin, Germany

6. Department of Medicine, University of Milan-Bicocca, Milan, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/08037051.2024.2329571

Reference13 articles.

1. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

2. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

3. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified

4. Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations

5. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension